Advertisement
Research Topics
Subscribe to Research Topics
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Drug Target Identified for Common Childhood Blood Cancer

July 31, 2014 1:13 pm | News | Comments

In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers report that they have identified a possible new drug target for treating the disease. Read more...

Gilead, Theraclone Partner on HIV Antibodies

July 31, 2014 9:46 am | News | Comments

Theraclone Sciences Inc. announced that it has entered into an agreement with Gilead Sciences Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV. Read more...

Cholesterol Drug Hits Primary Endpoint in Nine Trials

July 31, 2014 9:41 am | News | Comments

Sanofi and Regeneron announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator. Read more...

Advertisement

Naltrexone May Diminish ICD Symptoms in Parkinson's Patients

July 31, 2014 9:34 am | News | Comments

A team of investigators conducted a pilot study and found that the opioid antagonist naltrexone may be an effective treatment for diminishing symptoms of impulse control disorders (ICDs) in Parkinson's disease patients. Read more...    

New Mouse Model May Open Autism Treatment Avenues

July 31, 2014 9:23 am | News | Comments

Following a hunch about a brain receptor, researchers have developed a new mouse model that may open a new avenue for testing drugs for autism. Read more...                           

AstraZeneca, Almirall Strike Deal on Respiratory Franchise

July 31, 2014 9:17 am | News | Comments

AstraZeneca announced that it has entered an agreement to transfer to the company the rights to Almirall’s respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch and sales-related milestones. Read more...

France is 17th Country to Allow Patient Enrollment in Head, Neck Cancer Trial

July 31, 2014 8:44 am | News | Comments

CEL-SCI Corp. announced that the French Agency for the Safety of Health Products has cleared the company to commence patient enrollment for its Phase 3 Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection) in France. Read more...

Protein May Prevent Antibody-Mediated Transplant Rejection

July 31, 2014 8:40 am | News | Comments

A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. Read more...

Advertisement

CHMP Has More Issues with Weight Loss Drug

July 31, 2014 8:34 am | News | Comments

Orexigen Therapeutics Inc. announced it has received the Day 180 List of Outstanding Issues from the European Medicines Agency's Committee for Medicinal Products for Human Use for the NB32 (naltrexone sustained release (SR) / bupropion SR) Marketing Authorization Application. Read more...

Researchers ID New Malaria Vaccine Candidates

July 31, 2014 8:29 am | News | Comments

Researchers have discovered new vaccine targets that could help in the battle against malaria. Taking a new, large-scale approach to this search, researchers tested a library of proteins from the Plasmodium falciparum parasite with antibodies produced by the immune systems of a group of infected children. Read more...

Peptide Generates New Insulin-Producing Cells

July 31, 2014 8:23 am | News | Comments

A new study by researchers at Sanford-Burnham Medical Research Institute has found that a peptide called caerulein can convert existing cells in the pancreas into those cells destroyed in type 1 diabetes—insulin-producing beta cells. Read more...

Profectus BioSciences Snags $3.5M from NIH for HIV Vaccines

July 30, 2014 2:41 pm | News | Comments

Profectus BioSciences announced the award of two SBIR grants totaling $3.5 million from the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Read more...        

Treatment Combo Benefits Lung Cancer Patients

July 30, 2014 2:04 pm | News | Comments

A combination of the EGFR-targeted anticancer therapeutics Gilotrif and Erbitux yielded clinical responses in 29% of patients who had lung cancer harboring epidermal growth factor receptor mutations that had stopped responding to other inhibitors, according to new data. Read more...

Advertisement

New Route to ID Bacterial Infection Drugs

July 30, 2014 1:41 pm | News | Comments

About 100 drugs already approved by the FDA for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires’ disease, brucellosis, and Mediterranean spotted fever. Read more... 

Sage Licenses Gene Editing Tool from the Broad Institute

July 30, 2014 11:06 am | News | Comments

Sage Labs Inc., a leading provider of products, services and technologies in the field of genome engineering, announced that they have licensed CRISPR/Cas9 technology from the Broad Institute enabling them to use the CRISPR/Cas9 system to engineer cell and animal models for their clients as well as distribute validated CRISPR reagents. Read more...

Diabetes Drugs Get Positive CHMP Opinions for CV Safety Updates

July 30, 2014 10:58 am | News | Comments

Takeda Pharmaceuticals International GmbH announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics for Vipidia and the fixed-dose combination therapies Vipdomet and Incresync. Read more...

AstraZeneca, Kyowa Hakko Kirin Partner on Immuno-Oncology Study

July 30, 2014 10:48 am | News | Comments

AstraZeneca announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase 1/1b immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumors. Read more...

European Commission Approves Eliquis for DVT, PE

July 30, 2014 10:37 am | News | Comments

Bristol-Myers Squibb Co. and Pfizer Inc. announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. Read more...

Researchers to Study BRCA1-Related Breast Cancer

July 30, 2014 10:26 am | by Ashley WennersHerron, Virginia Tech | News | Comments

Deborah Kelly and Zhi Sheng, assistant professors at the Virginia Tech Carilion Research Institute, recently received a grant from the Commonwealth Health Research Board to investigate hereditary breast cancer, an effort that may lead to new treatment approaches. Read more...

Cancer Challenge Attracts Anonymous $100M Gift

July 29, 2014 2:54 pm | News | Comments

Oregon Health & Science University’s Knight Cancer Institute has received a $100 million gift to fuel its ambitious vision to stop cancer in its tracks. Read more...                       

Neurotrope Initiates Phase 2a Alzheimer's Treatment Study

July 29, 2014 2:48 pm | News | Comments

Neurotrope Inc. announced that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease (AD). Read more...                       

Forced Mutations Doom HIV

July 29, 2014 2:32 pm | News | Comments

Fifteen years ago, researchers thought if they could induce the HIV virus to mutate uncontrollably, they could force it to weaken and eventually die out. But in a 2011 clinical trial, a drug based on this method did not eliminate the virus from patients. Now, researchers are aiming to develop better versions of that drug. Read more...

$1,000 Sovaldi Now Choice Hep C Treatment

July 29, 2014 12:28 pm | by Ricardo Alonso-Zaldivar | News | Comments

The price may be high but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million. Read more...             

Glaucoma Drug Gets EU Approval

July 29, 2014 11:18 am | News | Comments

Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza eye drops suspension has been approved by the European Commission to decrease elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, for which monotherapy provides insufficient IOP reduction. Read more...

Artes, Burnet Institute Partner on Malaria Vaccine

July 29, 2014 11:13 am | by Catherine Somerville | News | Comments

Artes Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria Vaccine Initiative (MVI), which will produce purified vaccine antigens as virus-like particles, a type of nano-particle, for testing in laboratory studies. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading